Loading
OSE2101 is an experimental cancer vaccine from OSE Immunotherapeutics in phase 3 trials for non-small-cell lung cancer, aimed at HER2 and CEACAM5.
OSE2101 is a cancer vaccine developed by OSE Immunotherapeutics. Its targets are HER2, CEACAM5 and TP53 (the sponsor names P53, HER-2, CEA, MAGE-2, MAGE-3 (HLA-A2-restricted epitopes) plus PADRE pan-HLA-DR epitope). The sponsor states: A peptide vaccine composed of nine HLA-A2-restricted tumour-associated antigen epitopes plus one pan-HLA-DR binding epitope, emulsified in Montanide ISA 51 adjuvant, that activates tumour-specific T lymphocytes. ClinicalTrials.gov describes the intervention as: OSE2101 is a peptidic cancer vaccine composed of nine epitopes restricted to HLA-A2 phenotype targeting the tumour associated antigens of P53, HER-2, CEA, MAGE-2 and MAGE-3, and one pan-HLA DR binding epitope (PADRE), all epitopes emulsified. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06472245 (Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor), in non-small-cell lung cancer. The largest, NCT06472245, plans to enrol 363 participants with primary completion expected 2027-12-15. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
1.OSE2101 slips into a pocket on HER2.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"OSE2101" OR ABSTRACT:"OSE2101") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about OSE2101, not a curated reading list.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.
Shares CEACAM5 and the tag pipeline.
Shares HER2, Non-small-cell lung cancer and the tag pipeline.